IL28B, TLR7 SNPs, and cytomegalovirus infection are risk factors for advanced liver disease in chronic hepatitis C patients

References

• European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245–264.
   PubMed Web of Science ®Google Scholar
• Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–1284.
   PubMed Web of Science ®Google Scholar
• Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12(7):387–400.
   PubMed Web of Science ®Google Scholar
• Zeromski J, Kierepa A, Brzezicha B, et al. Pattern recognition receptors: significance of expression in the liver. Arch Immunol Ther Exp (Warsz). 2020;68(5):29.
   PubMed Web of Science ®Google Scholar
• Janovec V, Hodek J, Clarova K, et al. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Sci Rep. 2020;10(1):12767.
   PubMed Web of Science ®Google Scholar
• Niu C, Li L, Daffis S, et al. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. J Hepatol. 2018;68(5):922–931.
   PubMed Web of Science ®Google Scholar
• Fakhir FZ, Lkhider M, Badre W, et al. Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression. Liver Int. 2018;38(3):432–442.
   PubMed Web of Science ®Google Scholar
• Dominguez-Molina B, Machmach K, Perales C, et al. Toll-like receptor 7 (TLR-7) and TLR-9 agonists improve hepatitis C virus replication and infectivity inhibition by plasmacytoid dendritic cells. J Virol. 2018;92(23). doi:https://doi.org/10.1128/JVI.01219-18
   Google Scholar
• Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139(6):1865–1876.
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139(5):1586–92, 1592 e1.
   PubMed Web of Science ®Google Scholar
• McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138(7):2307–2314.
   PubMed Web of Science ®Google Scholar
• Fakhreddine AY, Frenette CT, Konijeti GG. A practical review of cytomegalovirus in gastroenterology and hepatology. Gastroenterol Res Pract. 2019;2019:6156581.
   PubMed Web of Science ®Google Scholar
• Lizaola-Mayo BC, Rodriguez EA. Cytomegalovirus infection after liver transplantation. World J Transplant. 2020;10(7):183–190.
   PubMedGoogle Scholar
• Tabll A, Shoman S, Ghanem H, et al. Assessment of human cytomegalovirus co-infection in Egyptian chronic HCV patients. Virol J. 2011;8(1):343.
   PubMedGoogle Scholar
• Bader El-din NG, Abd El-meguid M, Tabll AA, et al. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol. 2011;26(1):55–62.
   PubMed Web of Science ®Google Scholar
• Faivre M, Cottet V, Bour JB, et al. Impact of cytomegalovirus infection on the outcome of patients with cirrhosis: a preliminary study. J Clin Gastroenterol. 2019;53(3):236–241.
   PubMed Web of Science ®Google Scholar
• Arena U, Lupsor Platon M, Stasi C, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58(1):65–72.
   PubMed Web of Science ®Google Scholar
• De Ledinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices. 2010;7(6):811–823.
   PubMed Web of Science ®Google Scholar
• Abdelsameea E, Alsebaey A, Abdel-Razek W, et al. Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. Eur J Gastroenterol Hepatol. 2020;32(12):1553–1558.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Boom R, Sol C, Weel J, et al. A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence. J Clin Microbiol. 1999;37(5):1489–1497.
   PubMed Web of Science ®Google Scholar
• Dorak MT. Real-time PCR. Taylor & Francis; 2007; 333. https://doi.org/https://doi.org/10.4324/9780203967317
   Google Scholar
• Wang CH, Eng HL, Lin KH, et al. TLR7 and TLR8 gene variations and susceptibility to hepatitis C virus infection. PLoS One. 2011;6(10):e26235.
   PubMed Web of Science ®Google Scholar
• Yue M, Gao C-F, Wang J-J, et al. Toll-like receptor 7 variations are associated with the susceptibility to HCV infection among Chinese females. Infect Genet Evol. 2014;27:264–270.
   PubMed Web of Science ®Google Scholar
• El-Awady MK, Mostafa L, Tabll AA, et al. Association of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepatitis. 2012;12(4):271–277.
   PubMed Web of Science ®Google Scholar
• El Awady MK, Bader El Din NG, Tabll A, et al. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol. 2013;19(2):290–298.
   PubMed Web of Science ®Google Scholar
• Jordovic J, Simonovic-Babic J, Gasic V, et al. IL-28B genotypes as predictors of long-term outcome in patients with hepatitis C-related severe liver injury. J Infect Dev Ctries. 2019;13(6):526–535.
   PubMed Web of Science ®Google Scholar
• Ispiroglu M, Bahcecioglu IH, Demirel U, et al. Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta. J Infect Dev Ctries. 2017;11(1):58–64.
   PubMed Web of Science ®Google Scholar
• Schultheiss M, Thimme R. Toll like receptor 7 and hepatitis C virus infection. J Hepatol. 2007;47(2):165–167.
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology. 2005;42(3):724–731.
   PubMed Web of Science ®Google Scholar
• Schott E, Witt H, Neumann K, et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol. 2007;47(2):203–211.
   PubMed Web of Science ®Google Scholar
• Yue M, Feng L, Tang SD, et al. Sex-specific association between X-linked Toll-like receptor 7 with the outcomes of hepatitis C virus infection. Gene. 2014;548(2):244–250.
   PubMed Web of Science ®Google Scholar
• El-Bendary M, Neamatallah M, Elalfy H, et al. The association of single nucleotide polymorphisms of Toll-like receptor 3, Toll-like receptor 7 and Toll-like receptor 8 genes with the susceptibility to HCV infection. Br J Biomed Sci. 2018;75(4):175–181.
   PubMed Web of Science ®Google Scholar
• Wei XS, Wei CD, Tong YQ, et al. Single nucleotide polymorphisms of toll-like receptor 7 and toll-like receptor 9 in hepatitis C virus infection patients from central China. Yonsei Med J. 2014;55(2):428–434.
   PubMed Web of Science ®Google Scholar
• Ibrahim MK, Khedr A, Bader El Din NG, et al. Increased incidence of cytomegalovirus coinfection in HCV-infected patients with late liver fibrosis is associated with dysregulation of JAK-STAT pathway. Sci Rep. 2017;7(1):10364.
   PubMedGoogle Scholar